NEW YORK (GenomeWeb News) – Vermillion said today that its Ovarian Tumor Triage Test met its primary endpoints in a clinical study, and the firm will file for US Food and Drug Administration clearance of the test during the first half of this year, a company spokesperson told GenomeWeb Daily News.
The test is designed to stratify women with pelvic masses into high-risk and low-risk categories to help determine if they should be referred to a specialist prior to surgery.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.